JIR
BIIB icon

James Investment Research’s Biogen BIIB Stock Holding History

James Investment Research’s Portfolio BIIB Stock Details BIIB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-102
Closed -$28K – 582
2022
Q4 		$28K Buy
+102
New +$28.8K ﹤0.01% 412
2019
Q2 		– Sell
-2,200
Closed -$520K – 680
2019
Q1 		$520K Buy
+2,200
New +$693K 0.03% 448
2018
Q1 		– Sell
-5,400
Closed -$1.72M – 785
2017
Q4 		$1.72M Sell
5,400
-400
-7% -$128K 0.06% 388
2017
Q3 		$1.82M Buy
+5,800
New +$1.72M 0.06% 305
2014
Q1 		– Sell
-115
Closed -$32K – 510
2013
Q4 		$32K Hold
115
– – ﹤0.01% 398
2013
Q3 		$28K Hold
115
– – ﹤0.01% 401
2013
Q2 		$25K Buy
+115
New +$24.6K ﹤0.01% 396

Other funds holding BIIB

Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

James Investment Research's BIIB Position: Q1 2023 in Review

James Investment Research sold out of Biogen (BIIB) in Q1 2023, closing a stake of 102 shares — an estimated $28K sold.

James Investment Research first reported a position in BIIB in Q2 2013 and held it in 7 quarters. The position peaked at $1.82M in Q3 2017. 1,001 funds tracked by Wall St. Rank hold BIIB as of Q1 2023.

  • James Investment Research reported no remaining Biogen position as of Q1 2023 after selling out during the quarter.
  • James Investment Research sold 102 Biogen shares in Q1 2023, an estimated $28K.
  • James Investment Research first reported a position in Biogen in Q2 2013 and held it in 7 quarters.
  • James Investment Research's Biogen position peaked at $1.82M in Q3 2017.
  • 1,001 funds tracked by Wall St. Rank held Biogen as of Q1 2023.

Based on James Investment Research's 13F filing for Q1 2023, filed 26 Apr 2023.